Paola Rios Florez, MD
Endocrinology, Diabetes & Metabolism · Altoona, PANPI 1205322336
Payments from drug & device makers
Across 21 payments — averaging $67.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amryt Pharma Holdings Ltd$352
- AstraZeneca$281
- Medtronic$241
- Insulet Corporation$175
- Bayer$120
- Johnson & Johnson$102
- plus $141 from 2 others
What the payments were for
- Food & beverage$1,410100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amryt Pharma Holdings Ltd | 3 | $352 |
| AstraZeneca(2 entities) | 3 | $281 |
| Medtronic | 2 | $241 |
| Insulet Corporation | 2 | $175 |
| Bayer | 1 | $120 |
| Johnson & Johnson | 8 | $102 |
| BETA Bionics, Inc. | 1 | $77 |
| Amgen | 1 | $64 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYCAPSSA$352
- MINIMED 780G$157
- Strensiq$135
- Kerendia$120
- Omnipod$101
How this compares
$1,410 in reported general payments places this provider in the 50th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 232 | $353,120 |
| JardianceEmpagliflozin | 136 | $152,243 |
| MounjaroTirzepatide | 69 | $112,650 |
| TrulicityDulaglutide | 65 | $76,363 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 45 | $74,177 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $52,756 |
| Humalog Kwikpen U-200Insulin Lispro | 22 | $37,132 |
| Humalog Kwikpen U-100Insulin Lispro | 96 | $35,636 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 211 | $25,858 |
| TradjentaLinagliptin | 20 | $18,402 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $16,358 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $15,278 |
| Novolog FlexpenInsulin Aspart | 40 | $12,543 |
| JanuviaSitagliptin Phosphate | 13 | $12,281 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $11,287 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Altoona
- Mona Al MukaddamPhiladelphia$3.9M
- Serge JabbourPhiladelphia$3.1M
- Mihaela BiscoveanuPhiladelphia$1.5M
- Barbara SimonPhiladelphia$1M
- Mitchell LazarPhiladelphia$1M
- Vijay BahlPittsburgh$998K
- Intekhab AhmedPhiladelphia$926K
- Erin KershawPittsburgh$804K
- Geraldo SaavedraWhitehall$698K
- Arvind CavaleFeasterville Trevose$662K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.